Watertown-based Tome Biosciences launched in mid-December 2023 with $213 million in Series A and B funding from investors and moved to acquire California biotech Replace Therapeutics just two weeks later. Tome promises “to usher in a new era of genomic medicines based on programmable genomic integration (PGI).” PGI enables the insertion of any DNA sequence, […]

AstraZeneca has announced plans to acquire Seattle-based Icosavax, a clinical-stage biopharm focused on developing vaccines using a protein virus-like particle (VLP) platform. The proposed acquisition, valued at up to $1.1 billion, will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s late-stage pipeline with Icosavax’s lead investigational vaccine candidate, IVX-A12, a potential first-in-class, […]

Moderna and Merck have announced follow-up data from the Phase 2b clinical trial evaluating Moderna’s investigational INT (individualized neoantigen therapy) mRNA-4157 (V940) in combination with Merck’s Keytruda in patients with high-risk melanoma (Stage III/IV) following surgery. Treatment with the combination therapy reduced the risk of recurrence or death by 49% and the risk of developing […]

bluebird bio has announced FDA approval for the gene therapy Lyfgenia for the treatment of sickle cell disease. The therapy has been approved for patients ages 12 and older who suffer from debilitating pain crises due to the condition. The FDA action is the second such approval in as many days, the first belonging to […]

Cambridge-based Caraway Therapeutics has agreed to be acquired by pharma giant Merck for a total potential consideration of up to $610 million. Caraway describes itself as a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function and is utilizing its unique product […]

Less than a week after announcing its purchase of Waltham-based Immunogen for $10 billion plus – in one of the largest acquisitions of a Massachusetts company in 2023 – Abbvie has made another move, this time acquiring Cerevel Therapeutics of Cambridge for $8.7 billion. The Immunogen deal includes the company’s flagship cancer therapy Elahere, a […]